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Background: Liver steatosis is often found in association with common cardiometabolic disorders, conditions that
may all occur in a shared context of abdominal obesity and dyslipidemia. An algorithm for identifying liver
steatosis is the fatty liver index (FLI). The lipid accumulation product (LAP) is an index formulated in a
representative sample of the US population to identify cardiometabolic disorders. Because FLI and LAP share two
components, namely waist circumference and fasting triglycerides, we evaluated the ability of LAP to identify liver
steatosis in the same study population from the Northern Italian town where FLI was initially developed.
Methods: We studied 588 individuals (59% males) aged 21 to 79 years. Liver steatosis was detected by
ultrasonography and coded ordinally as none, intermediate and severe. 44% of the individuals had liver steatosis.
Using proportional-odds ordinal logistic regression, we evaluated the ability of log-transformed LAP (lnLAP) to
identify liver steatosis. We considered the benefits to our model of including terms for sex, age, suspected liver
disease and ethanol intake. We calculated the 3-level probability of liver steatosis according to lnLAP and sex,
providing tables and nomograms for risk assessment.
Results: An ordinal proportional-odds model consisting of lnLAP and sex offered a reasonably accurate
identification of liver steatosis. The odds of more severe vs. less severe steatosis increased for increasing values of
lnLAP (odds ratio [OR] = 4.28, 95%CI 3.28 to 5.58 for each log-unit increment) and was more likely among males
(OR = 1.88, 95%CI 1.31 to 2.69).
Conclusion: In a study sample of adults from Northern Italy, the simple calculation of LAP was a reasonably
accurate approach to recognizing individuals with ultrasonographic liver steatosis. LAP may help primary care
physicians to select subjects for liver ultrasonography and intensified lifestyle counseling, and researchers to select
patients for epidemiologic studies. A more thorough assessment of LAP’s potential for identifying liver steatosis will
require its cross-evaluation in external populations.
Background
Fatty liver is rapidly becoming the most common liver
disorder worldwide [1-4]. Many individuals with fatty
liver have also obesity, type 2 diabetes mellitus and
hypertriglyceridemia in the absence of relevant alcohol
intake, and they have multiorgan insulin resistance as a
hallmark feature [2,5]. Such variety of fatty liver is
known as non-alcoholic fatty liver disease (NAFLD) and
affects 20-30% of adults in the general population [3].
About 2-3% of the same population is estimated to have
non-alcoholic steatohepatitis (NASH), which is a stage
of NAFLD that may progress to liver cirrhosis [1,2].
Conventional descriptions of NAFLD depend on a
defined threshold estimate of fat content (>5%), but
steatosis in the liver is a graded phenomenon that is
monotonically associated with some physiologic impair-
ments [1,5]. From a public health perspective, irrespec-
tive of its binary (yes vs. no) or continuous definition, it
has become clear that NAFLD is associated with preva-
lent and incident cardiovascular disease and diabetes
[6-8]. Although it is not yet clear whether NAFLD has a
causative role in this respect, there are practical implica-
tions for the management of patients with NAFLD
[9,10].
With the aim of facilitating the detection of NAFLD in
the general population, we took advantage of the
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town of Northern Italy, to develop the “fatty liver index”
(FLI). FLI is a continuous measure that identifies the
binary condition of fatty liver [12]. FLI is based on body
mass index (BMI), waist circumference (WC), fasting
triglycerides, and gamma-glutamyl-transferase (GGT).
Interestingly, the Relationship between Insulin Sensitiv-
ity and Cardiovascular disease risk (RISC) Study has
shown that FLI is associated also with insulin resistance,
coronary heart disease, and early atherosclerosis in a
large European population [13]. FLI has also recently
been shown to be a predictor of 9-year incident diabetes
in the French Data from an Epidemiological Study on
the Insulin Resistance Syndrome (D.E.S.I.R.) Study [14].
One of us has used population-based data from a
United States’ National Health and Nutrition Examina-
tion Survey (NHANES III) to propose a “lipid accumu-
lation product” ( L A P )t h a td e p e n d so n l yo nt h e
measurement of WC and fasting triglycerides [15].
Cross-sectional analysis within NHANES III demon-
strated that LAP was superior to BMI in detecting some
prevalent cardiometabolic risk factors and diabetes
[15,16]. LAP predicts all-cause mortality [17], and is
presently being evaluated for its ability to predict inci-
dent cardiometabolic disease.
Because FLI and LAP share two predictors, namely
WC and fasting triglycerides, we considered it useful to
evaluate the ability of LAP, developed on a representa-
tive sample of the US population [15], for detecting liver
steatosis in the same Northern Italian study population
where FLI was developed [12]. Because the binary classi-
fication of liver steatosis into fatty liver (yes vs. no) has
the potential for losing information on a condition that
may be a graded cardiometabolic risk factor [5,18], we
evaluated liver steatosis as an ordinal 3-level variable.
Methods
Study design
The protocol of the Dionysos Nutrition and Liver Study
which is part of the larger Dionysos Project [19-21] and
was performed in 2001-2002, is described in detail else-
where [11]. Briefly, of the 5780 adult residents of Cam-
pogalliano (Modena, Emilia-Romagna, Italy), 3345 (58%)
agreed to participate to the study and 3329 (99%) of
them who had complete demographic data were consid-
ered for further evaluation. 497 (15%) of these 3329 par-
ticipants had suspected liver disease (SLD) according to
at least one of the following criteria: 1) alanine transa-
minase (ALT) > 30 U/L; 2) GGT > 35 U/L; 3) presence
of hepatitis B (HBV) surface antigen (HbsAg); 4) pre-
sence of hepatitis C virus (HCV) ribonucleic acid (RNA)
after detection of anti-HCV antibodies.
With the aim of enriching the analytic sample with
persons likely to have liver steatosis, we matched the
497 individuals who met the SLD criteria with an equal
number of individuals who had none of the SLD criteria.
The individuals without SLD were randomly selected
among the remaining 2832 participants with 1:1 match-
ing by sex and age (within 1 year). 324 individuals (65%)
in the SLD group and 335 (67%) in the no SLD group
agreed to undergo further evaluation and 311 (96%) and
287 (86%) of them had complete data. The present ana-
lysis includes 305 participants with SLD and 283 with-
out SLD on the basis of the availability of all
measurements of interest (n = 588).
Liver ultrasonography
Liver ultrasonography was performed using standardized
criteria by the same operator, who was unaware of the
clinical and laboratory data of the participants. Hepatic
steatosis was quantified with a method very similar to
that recently validated by Hamaguchi et al. [22]. Normal
liver was defined as the absence of liver steatosis or
other liver abnormalities. Light steatosis was defined as
t h ep r e s e n c eo fs l i g h t“bright liver” or hepatorenal echo
contrast without intrahepatic vessels blurring and no
deep attenuation; moderate steatosis as the presence of
mild “bright liver” or hepatorenal echo contrast without
intrahepatic vessel blurring and with deep attenuation;
and severe steatosis as diffusely severe “bright liver” or
hepatorenal echo contrast, with intrahepatic vessels
blurring (no visible borders) and deep attenuation with-
out visibility of the diaphragm. Because light and mod-
erate degrees of steatosis are difficult to distinguish and
had relatively small numbers in our sample, we pooled
together these degrees into one category which we have
called “intermediate steatosis”.
Clinical and laboratory assessment
Anthropometry was performed by two dietitians who
had been trained and certified before and during the
study. Weight and height were measured using standard
procedures [23] and WC was measured midway between
the lower rib margin and the iliac crest [24]. BMI was
calculated as weight (kg)/height (m)
2.
LAP was calculated by expressing waist enlargement
as the measured WC that exceeded a sex-specific mini-
mum WC value and then multiplying waist enlargement
by the concentration of fasting triglycerides [15]:
LAP for men = (WC [cm] - 65) × (triglycerides
[mmol/L])
LAP for women = (WC [cm] - 58) × (triglycerides
[mmol/L])
A seven-day diary was administered to the study parti-
cipants by two trained dietitians, who discussed it with
the participant when she/he returned it one week later
[25]. Daily ethanol intake was calculated as the mean
value of ethanol intake over a week.
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individuals with anti-HCV antibodies underwent an
HCV-RNA assessment to confirm HCV infection. ALT,
aspartate transaminase (AST), GGT, glucose, triglycer-
ides, and total cholesterol were measured by standard
laboratory methods after an overnight fast [11]. Diabetes
mellitus was defined as fasting blood glucose ≥ 126 mg/
dL or use of anti-diabetic drugs.
Ethical approval
The study protocol was approved and supervised by the
Scientific Committee of the Liver Research Center
(Basovizza, Trieste, Italy); all participants gave written
informed consent.
Statistical analysis




percentiles because of skewed distributions. The 3-level
outcome variable, hepatic steatosis assessed by liver
ultrasonography, was designated ordinally as none, inter-
mediate and severe. The Jonckheere-Terpstra test for
ordered alternatives (both ascending and descending)
was used to test the existence of a trend between ordin-
ally coded liver steatosis and LAP and the other vari-
ables of interest [26]. Fisher’se x a c tt e s tw a su s e dt o
evaluate the association between categorical variables
and liver steatosis [26].
A natural log-transformation of LAP (lnLAP) was per-
formed to ensure the equality of slopes among the levels
of the response variable, which is the basic assumption
made by the proportional-odds logistic model. We used
proportional-odds logistic regression to evaluate the
ability of lnLAP to predict liver steatosis, and we consid-
ered also alternative pre-specified models that included
covariate terms for sex (male vs. female), age (years),
SLD (yes vs. no) and ethanol intake (g/day). The odds
r a t i o( O R )o b t a i n e df r o mt h e s em o d e l si sam e a s u r eo f
the change in the odds from less severe to more severe
steatosis [27,28]. The main reason why we took sex, age
and SLD into account is that the Dionysos Nutrition
and Liver Study is a cross-sectional study with matching
of subjects performed on the basis of SLD, age and sex
[11].
The equality of slopes among the levels of liver steato-
sis was checked using the Brant test. Model fit was also
evaluated using standard diagnostic plots and the Hos-
mer-Lemeshow statistic for the 2 binary models under-
lying the proportional-odds model, i.e. none vs.
intermediate and severe steatosis and none and inter-
mediate vs. severe steatosis. The areas under the recei-
ver-operating characteristic curves (AUROC)
corresponding to these models were also calculated as
tests of model fit. We compared alternative models
using the Bayesian information criterion (BIC). When
comparing two models, “weak evidence” in favor of the
model with the lower BIC is said to exist when the BIC
difference (ΔBIC) is ≤ 2; “positive evidence” when 6 >
ΔBIC > 2; “strong evidence” when 6 ≤Δ BIC < 10; and
“very strong evidence” when ΔBIC > 10 [29,30].
All statistical tests were two-tailed and statistical sig-
nificance was assigned to a p-value < 0.05. Statistical
analysis was performed using Stata version 11.0 (Stata-
Corp, College Station, TX, USA).
Results
Table 1 reports the demographic, anthropometric, and
metabolic characteristics of the 588 participants (347
males [59%] and 241 females) stratified by the degree of
ultrasonographic liver steatosis. Owing to the study
design, approximately half (52%, n = 305) of the analytic
sample had suspected liver disease (SLD). Overall, 256
(44%) of the study participants had intermediate or
severe steatosis.
56% of the individuals (n = 332) had normal liver
while 20% (n = 118) had intermediate steatosis and 24%
(n = 138) had severe steatosis. Liver steatosis was more
common in males (none = 48%, intermediate = 23%,
severe = 29%) than in females (none = 69%, intermedi-
ate = 16%, severe = 15%; p < 0.001). The distribution of
liver steatosis in anti-HbsAg-positive group (n =2 3 )
was: none = 19, intermediate = 1, severe = 3; the corre-
sponding numbers for HCV-RNA-positive group
(n = 60) were 42, 12, 6.
Weight, BMI, WC, ALT, AST, GGT, ethanol intake,
glucose, triglycerides and LAP showed an increasing
trend for increasing degree of liver steatosis (p ≤ 0.006).
33 participants had diabetesa n d8o ft h e s eh a dn o r m a l
liver, 8 intermediate steatosis and 17 severe steatosis.
The median (25
th percentile, 75
th percentile) values of
LAP in 173 subjects aged 25 to 49 years and in 407
aged 50+ years were 26 (16, 47) and 37 (23, 63) as com-
pared to NHANES III population estimates of 30 (16,
57) and 53 (31, 85) [15].
Table 2 reports the proportional-odds logistic models
used to evaluate the association between lnLAP and
liver steatosis. Because the Dionysos Nutrition and Liver
Study is a cross-sectional study with matching of sub-
jects performed on the basis of SLD, sex and age [11],
we tested whether the addition of these variables had
a n ye f f e c to nt h ea b i l i t yo fl n L A Pt oi d e n t i f yl i v e r
steatosis.
Model 1 shows that for every increase in 1 unit of
lnLAP, the odds of more severe vs. less severe liver stea-
tosis was 4.45 (95%CI 3.42 to 5.79, p < 0.001). However,
the fit of Model 1 was not good, as detected by the Hos-
mer-Lemeshow statistic for the binary logistic model
aiming to discriminate none vs. intermediate and severe
liver steatosis (p = 0.008). Model 2 added sex and age to
Bedogni et al. BMC Gastroenterology 2010, 10:98
http://www.biomedcentral.com/1471-230X/10/98
Page 3 of 8Table 1 Measurements of the 588 study subjects.
None
n = 332,
M = 167, F = 165
Intermediate
n = 118,
M = 79, F = 39
Severe
n = 138,
M = 101, F = 37
JT test
p50 p25 p75 p50 p25 p75 p50 p25 p75 p-value
Age (years) 58 45 69 57 45 64 60 50 65 0.7
Ethanol (g/day) 9 0 27 9 0 28 16 2 43 0.006
Weight (kg) 69.5 61.5 76.5 78.7 71.0 89.0 83.4 75.5 93.2 <0.001
Height (m) 1.64 1.56 1.71 1.67 1.60 1.73 1.66 1.58 1.72 0.003
BMI (kg/m
2) 25.7 23.8 28.1 28.2 26.0 30.9 30.3 27.9 34.2 <0.001
Waist circumference (cm) 86.5 79.5 93.5 94.5 88.8 102.0 100.8 94.0 109.5 <0.001
ALT (U/L) 19 14 31 26 17 39 29 22 45 <0.001
AST (U/L) 21 17 26 21 18 28 24 20 30 <0.001
GGT (U/L) 18 13 27 27 17 43 36 23 61 <0.001
Glucose (mg/dl) 89 84 97 94 87 102 98 89 110 <0.001
Triglycerides (mg/dl) 90 65 123 115 88 162 149 98 205 <0.001
Total cholesterol (mg/dl) 211 183 236 212 184 238 216 184 244 0.2
LAP 24 15 39 43 27 62 63 36 93 <0.001
lnLAP 3.2 2.7 3.7 3.8 3.3 4.1 4.1 3.6 4.5 <0.001
Abbreviations: M = male; F = female; p50 = 50
th percentile (median); p25 = 25
th percentile (lower quartile); p75 = 75
th percentile (upper quartile); JT test =
Jonckerheere-Terpstra test for ordered alternatives (both ascending and descending); BMI = body mass index; ALT = alanine transaminase; AST = aspartate
transaminase; GGT = gamma-glutamyl-transferase; LAP = lipid accumulation product; lnLAP = natural logarithm of lipid accumulation product.
















4.45 4.42 4.28 4.25 4.14
lnLAP [3.42 to 5.79] [3.36 to 5.80] [3.28 to 5.58] [3.24 to 5.58] [3.17 to 5.40] p < 0.001
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Male sex – 1.78 1.88 1.72 1.79
[1.23 to 2.57] [1.31 to 2.69] [1.18 to 2.49] [1.25 to 2.58]
p = 0.002 p < 0.001 p = 0.004 p = 0.011
Age (years) – 0.99 – 0.99 –
[0.98 to 1.01] [0.98 to 1.01]
p = 0.232 p = 0.316
SLD –2; –– 1.70 1.72
[1.20 to 2.41] [1.21 to 2.44]
p = 0.003 p < 0.001
n 588 588 588 588 588
p-Brant test 0.560 0.518 0.704 0.273 0.331
p-HL none vs. intermediate + severe steatosis 0.021 0.402 0.836 0.584 0.315
p-HL none + intermediate vs. severe steatosis 0.236 0.383 0.398 0.594 0.676
AUROC 0.78 0.79 0.79 0.80 0.79
none vs. (intermediate + severe) steatosis [0.74 to 0.82] [0.76 to 0.83] [0.76 to 0.83] [0.76 to 0.83] [0.76 to 0.83]
AUROC 0.78 0.79 0.79 0.80 0.80
(none + intermediate) vs. severe steatosis [0.74 to 0.82] [0.75 to 0.83] [0.76 to 0.83] [0.76 to 0.84] [0.76 to 0.84]
BIC 1015 1014 1009 1012 1007
Abbreviations: OR = odds ratio; 95%CI = 95% confidence intervals; p-value = p-value for the regression coefficient (exponentiated and presented as odds ratio);
lnLAP = natural logarithm of the lipid accumulation product; SLD = suspected liver disease; p-Brant = p-value associated with the Brant test of proportional odds;
p-HL = p-value associated with the Hosmer Lemeshow statistics of the 2 binary models underlying the proportional-odds model; AUROC = area under the ROC
curve; BIC = Bayesian information criterion.
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of age on liver steatosis. Model 3 removed the non-sig-
nificant age term from Model 2 and offered “strong
evidence” of improvement as compared to Model 1
(ΔBIC = -6). Model 3 also fitted well according to the
Hosmer-Lemeshow statistics. Model 4 added SLD to the
predictors of Model 2. As the effect of age was still not
significant in Model 4, Model 5 evaluated the degree to
which the addition of SLD ameliorated the fit of Model
3.T h e r ew a so n l y“weak evidence” of improvement of
Model 5 vs. Model 3 (ΔBIC = -2), which is clearly not
counterbalanced by the difficulties in evaluating SLD in
epidemiological studies outside the field of hepatology.
The AUROC were similar for all models suggesting no
advantage in using the more complex models. However,
the AUROC does not address the issue of model cali-
bration so that it must be interpreted in the light of the
results of the other tests [31].
Because ethanol intake was higher in males than in
females, we tested whether it could be partly responsible
for the sex-related difference in the liver steatosis-lnLAP
association by adding it (g/day) to Models 1-5 but found
no association between it and liver steatosis (data not
shown). This finding was not unexpected owing to our
previous demonstration that alcohol intake was not a
predictor of binary fatty liver in this population [12] and
with the independent observation made by the RISC
Study that FLI and alcohol intake are not associated
[13].
Another possible explanation for the sex-related differ-
ence in the liver steatosis-lnLAP association could be
that we measured WC at the midpoint between the last
rib and the iliac crest [11,24] while LAP was developed
from the NHANES data using waist measured at level
of the iliac crest [15,32]. While these alternative WC
measurement protocols provide similar values in men,
in women the iliac-crest site may overestimate WC by
about 1.8 cm as compared to the site midway between
the last rib and iliac crest [33]. We tried to take into
account this difference by subtracting 1.8 cm from the
WC of our women and refitting Models 1-5 (data not
shown). The results were virtually unchanged as com-
pared to those provided in Table 2. This was not unex-
pected because the relationship between WC and health
outcomes is fairly stable independently from the mea-
surement site [34].
Owing to this evidence, we choose Model 3,b a s e do n
lnLAP and sex, as the most efficient and practical model
for predicting liver steatosis in our study population.
Figures 1 and 2 displays sex-specific probabilities of 3-
level liver steatosis as nomograms that illustrate the
continuous relationship of liver steatosis to lnLAP. The
Additional file 1 reports the probability of 3-level liver
steatosis for increments of 0.1 units in lnLAP in sepa-
rate tables for males and females.
Discussion
We evaluated whether LAP, developed as an index of
cardiometabolic risk in a representative sample of the
US population [15], could be employed as a predictor of
liver steatosis in the same Northern Italian study popu-
lation that was used to develop FLI [12]. We were
prompted to perform this evaluation because FLI, ori-
ginally derived to identify persons with fatty liver, has
recently been shown to identify cardiometabolic risk by
the RISC Study [13] and incident diabetes by the D.E.S.
I.R. Study [14]; FLI shares with LAP 2 of its 4 compo-
nents, namely WC and serum triglycerides.
We found that increasing values of LAP are associated
with increasing degrees of liver steatosis and that sex
has to be considered in this relationship. Although the
discriminative ability of lnLAP with respect to liver stea-
tosis was only modestly affected by sex, the inclusion of
sex in our ordinal logistic model improved model cali-
bration (Table 2). While the curves depicting the prob-
ability of liver steatosis as a function of lnLAP have a
similar shape in males and females, they tend to be
shifted to the right in the latter, indicating that males
have a higher probability of more severe steatosis at the
same value of LnLAP (Figures 1 and 2).
Our study has some limitations. First, although LAP
has the benefit of having been derived from a sample
that represented the US population (NHANES III) [15],
it has not been evaluated for the prediction of liver stea-
tosis in the same population. Thus, strictly speaking, our
study is not an external “validation” but an external
“evaluation” of LAP as simple index of liver steatosis.
Second, although the Dionysos Nutrition and Liver
Study was performed in a sample drawn from the gen-
eral adult population of a town in Northern Italy, this
population is not representative of Italy as a whole
[11,12]. LAP was independent from sex in the original
analysis [15] and the sex-lnLAP relationship observed in
the present study may be explained not only by the dif-
ferent outcome variable (liver steatosis vs. cardiovascular
risk factors) but also by local characteristics of the
population studied. Third, even if ultrasonography is at
present the most practical option to detect liver steatosis
in epidemiological studies, it underestimates the preva-
lence of fatty liver [2,3] and, more importantly, does not
offer information on the presence of NASH and liver
fibrosis [1-3]. However, in a clinical series of children
with NAFLD, we have recently reported that WC and
triglycerides can be used to predict the presence of liver
fibrosis, which is an “hard” hepatologic outcome [35].
Fourth, it remains to be tested whether the addition of
Bedogni et al. BMC Gastroenterology 2010, 10:98
http://www.biomedcentral.com/1471-230X/10/98
Page 5 of 8Figure 1 Probability of liver steatosis as detected by the natural logarithm of the lipid accumulation product in males. Abbreviations:
lnLAP = natural logarithm of LAP.
Figure 2 Probability of liver steatosis as detected by the natural logarithm of the lipid accumulation product in females. Abbreviations:
lnLAP = natural logarithm of LAP.
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the components which make up FLI - can improve the
identification of liver steatosis sufficiently to justify the
monetary and non-monetary costs associated with these
additional two components. Such a comparison should
performed in external populations because testing FLI
in the same population in which it was developed is
expected to overestimate its accuracy [36]. Fifth, the
ability of lnLAP to discriminate between intermediate
and severe steatosis is however limited up to values of
4.0 in males and 4.4 females (Figures 1 and 2). Whether
this is a true limitation of LAP will require epidemiolo-
gical studies trying to answer the more fundamental
question whether the fat content of the liver is asso-
ciated with hard clinical outcomes as it is for some phy-
siological outcomes [5].
The association between LAP, liver steatosis and car-
diometabolic disease [15,16] might be partially explained
by a common pathophysiological milieu. Besides being a
recognized risk factor for cardiovascular disease [34],
waist circumference is a surrogate measure of visceral
fat, which is the most abundant form of ectopic fat and
which is thought to play a major role in insulin resis-
tance and lipotoxicity [37,38]. Serum triglycerides are
commonly elevated in the presence of insulin resistance
and hyperlipidemia, a recognized risk factor for cardio-
vascular disease, is strongly associated with hepatic tria-
cyglicerol content [6]. The existence of a liver-vessel
axis has been recently hypothesized to explain the asso-
ciation between NAFLD and cardiovascular disease [6].
Moreover, recent publications suggest that steatosis in
t h el i v e rm a yb et h ef i r s t[ 3 9 ]o rt h eb e s t[ 4 0 ]m a r k e r
associated with cardiometabolic risk. LAP may thus be
valuable for recognizing patients likely to have insulin
resistance along with ectopic lipid deposition also in
non-hepatic tissues [41].
Conclusion
LAP, developed as a marker of cardiometabolic risk in a
representative sample of the US population, proved also
to be a simple and reasonably accurate predictor of
ultrasonographic liver steatosis in a study sample
derived from the adult population of a town in Northern
Italy. LAP may help primary care physicians to select
subjects for liver ultrasonography and intensified lifestyle
counseling, and researchers to select patients for epide-
miologic studies. LAP, a continuous index that can vary
independently of body weight [42], may also be useful
for the low-cost monitoring of metabolic deterioration
or the benefits associated with exercise, diet, behavior
therapy or pharmacological treatments. A more thor-
ough test of LAP’s potential for identifying liver steatosis
and its changes following treatment will require its
cross-evaluation in external populations.
Additional material
Additional file 1: Probability of liver steatosis as detected by the
natural logarithm of the lipid accumulation product in males and
females. Abbreviations; LAP = lipid accumulation product; lnLAP =
natural logarithm of LAP; Prob = probability; Lower = lower 95%
confidence interval; Upper = upper 95% confidence interval.
Abbreviations
95%CI: 95% confidence interval; ALT: alanine transaminase; AST: aspartate
transaminase; BIC: bayesian information criterion; BMI: body mass index; D.E.
S.I.R.: Data from an Epidemiological Study on the Insulin Resistance
Syndrome Study; FLI: fatty liver index; GGT: gamma-glutamyl-transferase;
HbsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCV: hepatitis C
virus; HCV-RNA: ribonucleic acid of hepatitis C virus; LAP: lipid accumulation
product; LnLAP: natural logarithm of lipid accumulation product; NAFLD:
non-alcoholic fatty liver disease; NHANES: National Health and Nutrition
Examination Survey; OR: odds ratio; RISC: Relationship between Insulin
Sensitivity and Cardiovascular disease risk Study; SLD: suspected liver disease;
WC: waist circumference.
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